Member Info for Laura2022

There was a delayed buy which filled during that time period Kidlington

The grey trade at the end of the day

They are buys and not sure why some people would claim otherwise

2.2. Going Concern

Notwithstanding the loss from continuing operations for the six month period to June 2023, the directors have prepared the unaudited interim financial information under the going concern basis.

As part of normal business practice, the Group prepares monthly detailed financial forecasts which incorporate year-to-date performance and scenario planning. The Directors have considered the cashflow requirements of the Group and concluded will have sufficient funds to meet its financial liabilities as and when they fall due, for a period of at least 12 months from the date of this report. 

You could imagine a few looking at PYC as a good addition to their in house R and D

Thanks newucncle for the info on AVACTA

Maybe a good fit to buy Pyc?

Just shown

Just now ?

No , I have added approximately £18,000

Looks like Rightback did mot qchieve his 1.5p

There have been 3 cyber security takeovers and 2 bio techs so far in the last 5 weeks , on another board they are saying AVICTA/AVCT? Would be interested

Does anyone know what they do ?

Brighton mentioned El Lilly ??

3p us still only £4mln too Brighty

Yiu thought rightly that £25mln wold be fair

This morning with profits from FCS

Thanks msuk/sienna

Hi Mark

What does that black triangle mean ?

Is I t a good symbol ?

A.I yet again developing and I'm sure we are in the frame given the comments from Jim Millen at the end of the last PYC Merck RNS

Beyond Blood is just one option for their dosing tool,this was from the January news item

NEXT STEPS

There are multiple ways in which the results of the PARTNER study can be leveraged:

· Academic dissemination; the insights gained from the PARTNER study will form the basis of several posters and/or publications

· The exploring of solutions for point of care blood testing that could address the limitation noted above. Physiomics has already identified a number of technologies in development that could be the basis for a hardware/ software collaboration

· Exploring other applications of the tool in settings where regular attendance at hospital for additional tests is not an obstacle because it is already required as part of current standard of care or because the use of the drug requires careful monitoring; examples could include:

o  Paediatric applications where it is important to maintain certain cell types within strict limits

o  Patients with haematological malignancies

o  Patients undergoing chemotherapy in combination with radiotherapy

You could not buy at 1.8p at the last few minutes

Falling knife post from early August,

Good morning Noel. 15p may come and i know u are being facetious about this week being the week but the one certaint is the dribbly one and Razza b and 1 squadron would be still talking about moonshots and turnarounds here. Unbelievable that people can be so gullible

Have they deliberately chosen to show this buy as a sell ?

Thankyou trench

This PYC dosing tool really could be revolutionary as your summary confirms

The £6,000 is a buy